The KIF2A Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from A-549 cells, designed to disrupt expression of the KIF2A gene. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, resulting in a heterogeneous pool of edited cells that enables robust downstream analyses of KIF2A-dependent processes. As a polyclonal knockout product, it avoids clonal artifacts and provides a cost-effective tool for high-content screening and mechanistic studies where clonal purity is not required.
The host cell line, A-549, is a widely used human lung adenocarcinoma epithelial cell line originally established from a 58-year-old Caucasian male with lung cancer. These cells exhibit adherent, epithelial morphology and serve as an important in vitro model for Type II alveolar epithelial cells and lung adenocarcinoma biology. Their well-characterized genomic landscape and amenability to genetic manipulation make them suitable for investigating tumorigenesis, drug response, and cellular signaling pathways.
KIF2A is a kinesin-13 family microtubule depolymerase that utilizes ATP hydrolysis to depolymerize microtubules, a function critical for mitotic spindle assembly, chromosome congression, and proper chromosome segregation. Its activity is tightly regulated by mitotic kinases, being phosphorylated by Aurora B kinase, PLK1, and CDK1, and it interacts with TPX2 and CENP-E at kinetochores and spindle microtubules. KIF2A-mediated microtubule depolymerization is essential for maintaining spindle dynamics and ensuring the fidelity of cell division. Beyond mitosis, KIF2A contributes to microtubule cytoskeleton organization in interphase and plays a key role in neuronal migration during development; mutations in this gene are associated with cortical dysplasia, complex, with other brain malformations (CDCBM3), underscoring its significance in both proliferative and differentiative contexts.
In the context of A-549 lung adenocarcinoma cells, disruption of KIF2A is expected to severely impair mitotic progression, leading to chromosome misalignment, activation of the spindle assembly checkpoint, and aberrant cell division. This knockout model provides a unique opportunity to dissect how KIF2A loss impacts cancer cell proliferation, mitotic fidelity, and the response to therapeutics that target mitotic machinery or microtubule dynamics. Researchers can explore synthetic lethal interactions or evaluate vulnerabilities exposed by KIF2A deficiency in a lung cancer background.
This polyclonal knockout cell population is suitable for a broad range of research applications, including detailed analysis of mitotic spindle assembly, cell cycle regulation, and microtubule dynamics. It is an ideal tool for drug development programs screening inhibitors against mitotic regulators such as Aurora B or PLK1, as well as for neurodevelopmental disorder modeling related to KIF2A dysfunction. Typical assays include western blotting and RT-qPCR to confirm KIF2A disruption, immunofluorescence to visualize spindle morphology, flow cytometry for cell cycle and proliferation analysis, live-cell imaging of mitotic progression, and RNA-seq to capture transcriptome changes. For further information or custom inquiries, please contact Ascent Research.
